Lushang Freda Pharmaceutical Co., Ltd. Class A

Lushang Freda Pharmaceutical Co., Ltd. Class A

SSSE:600223
5.26
CNY
-0.02
(-0.38%)
0.20EPS
37.58P/E
5.84BMarket Cap
Mar 22Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
5.23
5.78
5.73
7.45
8.41
8.71
10.15
13.64
12.3
11.4
4.53
3.92
3.5
3.72
Basic EPS, GAAP
0.26
0.21
0.11
0.09
0.13
0.16
0.34
0.64
0.36
0.04
0.3
0.24
0.18
0.15
Free Cash Flow per Basic Share
-1.09
-2.41
-1.77
-2.43
1.58
2.04
-3.32
4.3
6.53
0.73
0.26
0.07
0.16
- -
Dividend per Share
0.73
0.37
0.43
0.61
0.67
0.73
1.71
2.27
2
1.03
0.48
0.18
0.06
0.06
Book Value per Share
1.84
2.02
2.13
2.22
2.69
2.44
2.74
4.04
4.68
3.66
3.95
4.04
4.16
4.22
Tangible Book Value per Share
1.77
1.96
2.07
2.16
2.51
2.26
2.56
3.67
4.3
3.28
3.62
3.69
3.81
3.85
Basic Weighted Avg Shares
1,012
983
1,023
1,026
985
1,013
1,013
998
1,005
1,136
1,011
1,015
1,043
1,028
Sales/Revenue/Turnover
5,293
5,682
5,864
7,646
8,287
8,821
10,289
13,615
12,363
12,951
4,579
3,983
3,651
3,829
Operating Margin (%)
10.78
6.81
4.84
2.78
4.3
5.62
4.66
5.87
6.99
6.81
6.74
6.96
5.7
5.08
Depreciation Expense
33
33
29
31
67
67
64
86
94
122
148
102
108
- -
Net Income, GAAP
263
206
112
92
128
162
345
639
362
45
303
244
188
157
Effective Tax Rate (%)
33.2
34.02
44.7
49.24
47.35
48.69
30.73
25.15
38.83
75.06
11.34
14.4
16.64
16.44
Profit Margin (%)
4.97
3.63
1.92
1.21
1.55
1.84
3.35
4.69
2.93
0.35
6.63
6.11
5.14
4.1
Working Capital
3,878
5,088
6,128
12,011
7,840
7,373
6,913
8,631
7,577
5,023
3,583
3,037
3,137
3,224
LT Debt
2,340
3,409
4,451
10,284
6,098
5,886
3,780
4,430
3,759
2,237
678
52
10
8
Total Equity
2,024
2,252
2,411
2,549
3,192
2,894
4,696
6,517
6,500
5,567
4,680
4,788
4,948
5,011
Return on Invested Capital (%)
7.56
4.12
1.82
0.93
1.28
1.78
2.74
3.78
2.36
0.51
3.56
4.88
4.74
3.95
Return on Capital (%)
3.29
2.85
1.48
0.77
0.8
0.97
2.52
4.24
2.36
0.86
3.22
3.51
2.81
2.26
Return on Common Equity (%)
15.47
10.68
5.41
4.23
5.21
6.32
13.29
18.72
8.22
1.08
7.85
6
4.5
3.72

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
166
89
72
LT Borrowings
6
6
6
LT Finance Leases
4
2
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,017
1,017
1,017
Market Capitalization
6,994
5,113
5,835

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
4,064
4,105
3,908
Cash, Cash Equivalents & STI
2,873
2,876
2,757
Accounts Receivable, Net
480
500
489
Inventories
452
500
437
Total Current Liabilities
882
903
683
Payables & Accruals
- -
- -
- -
ST Debt
166
89
72
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.78%
-4.98%
3.33%
Free Cash Flow
-62.61%
-8.68%
132.1%
Net Income, GAAP
63.93%
78.81%
-22.9%
Sales/Revenue/Turnover
0.37%
-18.09%
-8.33%
Total Cash Common Dividend
-1.19%
-47.62%
-64.48%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
891
1,035
877
1,180
3,983
2025
876
913
- -
1,054
3,651
2026
900
1,009
865
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.06
0.07
0.04
0.07
0.24
2025
0.05
0.06
- -
0.05
0.18
2026
0.03
0.05
0.03
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
- -
0.11
0.05
0.18
2025
- -
- -
- -
- -
0.06
2026
- -
- -
0.06
- -
- -

Company Description

CEO
Chun Ming Gao
Full Time Employees
3,514
Sector
Finance
Industry
Real estate development
Address
No. 888, High-tech Zone Jinan SD China 250101
IPO Date
Jan 13, 2000
Business
Lushang Freda Pharmaceutical Co., Ltd. (600223.SS) is a China-based company primarily engaged in the research, development, production, and sale of pharmaceuticals and cosmetics. The company offers a broad portfolio of products, including Chinese patent medicines, chemical medicines, and health foods across orthopedics, gynecology, internal medicine, ophthalmology, and pediatrics; cosmetics such as cleansers, lotions, creams, essences, and masks under brands like Yilian (Lotus Care), Aier Boshi (Dr. Alva), Yipaerhan (Ile Fragrance), Mingren, Runjie, and Special; active pharmaceutical ingredients (APIs), medical devices, health supplements, and functional foods; as well as synthetic biological materials like hyaluronic acid (HA), where it leads China's industry, food additives including Natamycin and Nisin, and natural cosmetic ingredients such as Ectoin, Sodium Polyglutamate, and Pullulan. Founded in 1993 and headquartered in Jinan, Shandong Province, China, the company operates seven specialized production bases in Jinan, Linyi, Jining, and Yili (Xinjiang), with products distributed to over 70 countries in North America, the European Union, Japan-Korea, and Southeast Asia. It maintains subsidiaries and operates as a subsidiary of Shandong Freda Biological Co., Ltd., with a strong emphasis on innovation through four national-level R&D platforms, 17 provincial facilities, and collaborations with institutions like Zhejiang University and the Shanghai Institute of Materia Medica. In recent developments, the company reported first-half 2025 revenue of CNY 1.79 billion, down 7.1% year-over-year, with net profit attributable to shareholders at CNY 108 million, down 15.2%, reflecting steady growth in the Yilian brand amid adjustments to the Aier Boshi brand. It announced plans to divest its wholly-owned subsidiary Shandong Lushang Inzone Commercial Management for approximately CNY 88.4 million in October 2025, focusing on core pharmaceutical and cosmetics operations. Additionally, in February 2024, it sold an equity interest in Daantong to Lushang Life Services Co., Ltd. as part of portfolio streamlining.